POLYDEOXYRIBONUCLEOTIDES ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
51全身性強皮症2
70広範脊柱管狭窄症1

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03388255
(ClinicalTrials.gov)
November 8, 201621/12/2017Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma DiseasesA Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma DiseasesScleroderma DiseaseDrug: PolydeoxyribonucleotidesMastelli S.r.lSintesi Research SrlTerminated18 YearsN/AAll25Phase 4Italy
2EUCTR2015-005100-28-IT
(EUCTR)
18/07/201617/01/2022A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in patients with cutaneous lesions in scleroderma diseases.A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroderma diseases. - A clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ administered intra-muscular in p Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases.
MedDRA version: 20.0;Level: HLT;Classification code 10039711;Term: Scleroderma and associated disorders;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿
Product Name: PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml
INN or Proposed INN: POLYDEOXYRIBONUCLEOTIDES
Other descriptive name: PLACENTEX ® Polydeoxyribonucleotide
MASTELLI SRLNULLNot RecruitingFemale: yes
Male: yes
45Phase 4Italy

70. 広範脊柱管狭窄症


臨床試験数 : 95 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04401735
(ClinicalTrials.gov)
November 1, 201911/5/2020Effects and Safety of Epidural PDRN vs. PlaceboEffects and Safety of PDRN (Polydeoxyribonucleotide) for Patient With Lumbar Spinal Stenosis Compared With Normal Saline in Randomized Placebo-Controlled Comparative Pilot StudySpinal Stenosis LumbarDrug: Polydeoxyribonucleotides;Drug: Normal salineSeoul National University HospitalNULLRecruiting19 Years80 YearsAll45Phase 4Korea, Republic of